Nutrition and metabolismTreating dyslipidemia in the elderlyPohlel, Khana; Grow, Parkera; Helmy, Tareka,b; Wenger, Nanette Ka,bAuthor Information aEmory University School of Medicine bGrady Memorial Hospital, Atlanta, Georgia, USA Correspondence to Professor Nanette K Wenger MD, FACC, Professor of Medicine and Cardiology, Emory University School of Medicine, and Chief of Cardiology, Grady Memorial Hospital, 49 Jesse Hill Jr Drive SE, Atlanta, GA 30303, USA Tel: +1 404 616 4420; fax: +1 404 616 3093; e-mail: [email protected] Current Opinion in Lipidology: February 2006 - Volume 17 - Issue 1 - p 54-57 doi: 10.1097/01.mol.0000199812.00978.ac Buy Metrics Abstract Purpose of review The treatment of dyslipidemia has been dynamic over the past several years. Of special importance is the impact of recent clinical trial data on management strategies of dyslipidemia in the elderly. People 65 years and older are living longer and are the fastest growing subset of the US population, necessitating more attention to chronic disease conditions that manifest in this age group. This review addresses guidelines of lipid management, discusses data that support their use, and examines the benefits of lipid-lowering therapy in the elderly with attention to the chronic conditions that are common in this population. Recent findings Clinical trials completed since the publication of the 2001 National Cholesterol Education Program (NCEP) Adult Treatment Panel III guidelines support the use of lipid-lowering therapy in the elderly population. Lipid-lowering therapy has not only proven to be generally safe in the elderly, but has also proven effective in helping manage the chronic disease conditions that are common in this age group. Summary The elderly segment of our population continues to grow. Along with this growth in population is a growth in incidence of cardiovascular disease, the metabolic syndrome, chronic kidney disease, cerebrovascular disease, and diabetes mellitus. There is no known panacea for managing these chronic disease conditions; however, lipid-lowering therapy has been shown to prevent or delay the progression of these diseases and the mortality and morbidity that accompanies them. © 2006 Lippincott Williams & Wilkins, Inc.